Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results

Arias, Luis; Planas, Núria; Prades, Sergi; Caminal, Josep M.; Rubio, Marc; Pujol, O.; Roca, Gustavo Rioja

doi:10.1136/bjo.2007.130260

Cited by 64 publications

(40 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[21][22][23] Treatment outcomes after intravitreal bevacizumab in 15 studies are summarised in Table 1. [24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] A cumulative analysis of all study data reveals the following trends. Of all studies examined, a total of 181 eyes received treatment for naïve lesions, and 74 eyes were treated earlier.…”

Section: Pathological Myopiamentioning

confidence: 99%

See 1 more Smart Citation

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

Choroidal neovascularisation (CNV) is characterised by new blood vessel growth under the retina that usually results in significant visual impairment when the fovea is involved. Though CNV is more commonly associated with age-related macular degeneration (AMD), it can occur secondary to a variety of other diseases. Recent successes with anti-angiogenic therapies suggest that they may outperform other therapies for all types of CNV. As non-AMD-related CNV cases are rare, randomised controlled trials are often not possible. This review compares the less prevalent reports of non-AMD CNV and pools evidence on the success and limitations of a variety of therapies.

show abstract

Section: Pathological Myopiamentioning

confidence: 99%

“…There were few reported complications; there was only one case each of retinal detachment, 28 RPE rip, 24 and low grade iridocyclitis. 30 These pooled 12-month data suggest that visual outcomes with bevacizumab treatment are better than other available options for myopic CNV.…”

mentioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

show abstract

“…On the other hand, OCT has played a useful role in guiding retreatment in most studies evaluating the efficacy of anti-VEGF therapy in myopic CNV, whereas no study has specifically addressed the option of using OCT instead of FA [7,8,9,10,11,12,13,14,15,16,17]. …”

Section: Introductionmentioning

confidence: 99%

Fluorescein Angiography and Spectral-Domain Optical Coherence Tomography for Monitoring Anti-VEGF Therapy in Myopic Choroidal Neovascularization

et al. 2014

View full text Add to dashboard Cite

Aim: To evaluate the agreement between fluorescein angiography (FA) and spectral-domain optical coherence tomography (SD-OCT) in detecting myopic choroidal neovascularization (CNV) activity during bevacizumab treatment. Methods: Thirty-four patients with subfoveal myopic CNV were prospectively enrolled. FA and SD-OCT were performed at baseline and at all planned monthly visits. After the first injection, additional treatments were administered following detection of fluid on SD-OCT and/or leakage on FA. κ-Analysis was performed to examine the agreement between FA and SD-OCT. Results: At baseline, FA and SD-OCT agreed in 26/34 cases (κ = 0.23); sensitivity and specificity were 77.4 and 66.7%, respectively. Seven eyes presented leakage on FA with no fluid on SD-OCT, 1 case showed intraretinal fluid on SD-OCT and no leakage on FA. At the 1-month examination, specificity and κ-value improved, and 30/34 cases showed complete concordance. At the 3- and 4-month examinations, a discordance was noted in 6 cases. From the 5-month examination on, a correspondence was achieved in at least 30/34 cases and reached a perfect match in 11 sessions. Conclusions: Our study confirms the key role of FA in diagnosing myopic CNV. It seems possible there may be a role for SD-OCT in assisting FA to monitor the myopic CNV activity during anti-vascular endothelial growth factor antibody treatment.

show abstract

“…Recently, several studies have reported the effects of intravitreal bevacizumab injections on reducing macular edema and retinal/choroidal neovascularization in patients with age-related macular degeneration (AMD), diabetic retinopathy, central vein occlusion, and degenerative myopia. [7][8][9][10][11] The most common adverse effects of systemic bevacizumab include hypertension, proteinuria, hemorrhage, thromboembolic events, and gastrointestinal perforation. 5 Michels et al 12 reported a mild elevation of systolic blood pressure after systemic bevacizumab administration for neovascular AMD.…”

Section: Introductionmentioning

confidence: 99%

Effects of intravitreal injection of bevacizumab on nitric oxide levels

Dinç

Yıldırım

Ayaz

et al. 2014

Eye

View full text Add to dashboard Cite

Purpose This study aimed to determine the possible effects of single-dose intravitreal bevacizumab on nitric oxide (NO) levels in serum and remote organs and to reveal one of the possible mechanisms in the pathophysiology of hypertension. Methods Thirty-eight adult New Zealand albino rabbits were divided into a control group (no injection was performed, killed on day 28 of the study), group 1 (killed on day 1 of the study), group 2 (killed on day 7 of the study), group 3 (killed on day 14 of the study), and group 4 (killed on day 28 of the study). The right eyes of the animals in groups 1-4 received an intravitreal single injection of 1.25 mg (0.05 ml) bevacizumab (Avastin), and their brain, heart, liver, kidney, and blood samples were collected. NO levels were evaluated in the serum and organ homogenates. Kidney tissues were assessed by electron microscopy. Results Serum, brain, kidney, and liver NO levels significantly decreased in groups 2, 3, and 4 as compared with the control group (Po0.05). In addition, heart NO levels significantly decreased in groups 3 and 4 compared with the control group (Po0.05). There were no electron microscopic changes in the kidneys of either group. Conclusions This study demonstrated that single intravitreal injection of bevacizumab decreased NO levels in serum, brain, heart, liver, and kidneys. In addition, there were no electron microscopic changes in the kidneys.

show abstract

Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results

Abstract: In our study, intravitreal bevacizumab appeared to be safe and efficacious in eyes with CNV secondary to PM.

Cited by 64 publications

References 16 publications

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Fluorescein Angiography and Spectral-Domain Optical Coherence Tomography for Monitoring Anti-VEGF Therapy in Myopic Choroidal Neovascularization

Effects of intravitreal injection of bevacizumab on nitric oxide levels

Contact Info

Product

Resources

About